{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:44:02Z","timestamp":1790837042342,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Diabetic kidney disease (DKD) is one of the most common complications of diabetes, and the most common cause of end-stage renal disease, for which no effective therapies are yet available. RNA-binding proteins (RBPs) play a pivotal role in epigenetic regulation; tristetraprolin (TTP) and human antigen R (HuR) competitively bind cytokine mRNAs, exert contrasting effects on RNA stability, and drive inflammation. However, RBPs\u2019 roles in diabetes-related glomerulopathy are poorly understood. Herein, we investigated whether TTP and HuR are involved in post-transcriptional regulation of podocytopathic molecules and inflammatory cytokines in DKD. In DKD patients and\n                    <jats:italic>db\/db<\/jats:italic>\n                    mice, TTP expression was significantly decreased and HuR expression was increased in glomerular podocytes, concurrent with podocyte injury, histological signs of DKD, and augmented glomerular expression of interleukin (IL)-17 and claudin-1, which are targets of TTP and HuR, as evidenced by RNA immunoprecipitation. In cultured podocytes, exposure to high ambient glucose amplified HuR expression and repressed TTP expression, upregulated IL-17 and claudin-1, and promoted podocyte injury. Thus, TTP hypoactivity or HuR hyperactivity is sufficient and essential to diabetic podocytopathy. Moreover, in silico analysis revealed that several kinases govern phosphorylation and activation of TTP and HuR, and glycogen synthase kinase (GSK)-3\u03b2 activated both TTP and HuR, which harbor putative GSK-3\u03b2 consensus phosphorylation motifs. Treatment of\n                    <jats:italic>db\/db<\/jats:italic>\n                    mice with a small molecule inhibitor of GSK-3\u03b2 abrogated the changes in TTP and HuR in glomeruli and mitigated the overexpression of their target genes (\n                    <jats:italic>IL-17<\/jats:italic>\n                    ,\n                    <jats:italic>claudin-1<\/jats:italic>\n                    ,\n                    <jats:italic>B7-1<\/jats:italic>\n                    , and\n                    <jats:italic>MCP-1<\/jats:italic>\n                    ) thus also mitigating proteinuria and DKD pathology. Our study indicates that TTP and HuR are dysregulated in DKD via a GSK-3\u03b2-mediated mechanism and play crucial roles in podocyte injury through post-transcriptional regulation of diverse genes. It also provides novel insights into DKD\u2019s pathophysiology and identifies potential therapeutic targets.\n                  <\/jats:p>","DOI":"10.1038\/s41419-020-2630-x","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T05:11:48Z","timestamp":1591074708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["RNA-binding proteins tristetraprolin and human antigen R are novel modulators of podocyte injury in diabetic kidney disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Jia","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengwen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6302-2800","authenticated-orcid":false,"given":"Rujun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangsuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"2630_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5414\/CN109606","volume":"92","author":"W Pichaiwong","year":"2019","unstructured":"Pichaiwong, W., Homsuwan, W. & Leelahavanichkul, A. The prevalence of normoalbuminuria and renal impairment in type 2 diabetes mellitus. Clin. Nephrol. 92, 73\u201380 (2019).","journal-title":"Clin. Nephrol."},{"key":"2630_CR2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMc1602469","volume":"375","author":"L Zhang","year":"2016","unstructured":"Zhang, L. et al. Trends in chronic kidney disease in China. N. Engl. J. Med. 375, 905\u2013906 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2630_CR3","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.kint.2016.01.012","volume":"89","author":"M Nagata","year":"2016","unstructured":"Nagata, M. Podocyte injury and its consequences. Kidney Int. 89, 1221\u20131230 (2016).","journal-title":"Kidney Int."},{"key":"2630_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000368940","volume":"39","author":"OM Akchurin","year":"2015","unstructured":"Akchurin, O. M. & Kaskel, F. Update on inflammation in chronic kidney disease. Blood Purif. 39, 84\u201392 (2015).","journal-title":"Blood Purif."},{"key":"2630_CR5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/13543784.2018.1538352","volume":"27","author":"JA Moreno","year":"2018","unstructured":"Moreno, J. A. et al. Targeting inflammation in diabetic nephropathy: a tale of hope. Expert Opin. Investig. Drugs 27, 917\u2013930 (2018).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2630_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cyto.2014.10.009","volume":"72","author":"R Vasanthakumar","year":"2015","unstructured":"Vasanthakumar, R. et al. Serum IL-9, IL-17, and TGF-beta levels in subjects with diabetic kidney disease (CURES-134). Cytokine 72, 109\u2013112 (2015).","journal-title":"Cytokine"},{"key":"2630_CR7","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s00125-011-2237-y","volume":"54","author":"F Liu","year":"2011","unstructured":"Liu, F. et al. C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes. Diabetologia 54, 2713\u20132723 (2011).","journal-title":"Diabetologia"},{"key":"2630_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00125-015-3766-6","volume":"59","author":"R Bassi","year":"2016","unstructured":"Bassi, R., Fornoni, A., Doria, A. & Fiorina, P. CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease. Diabetologia 59, 21\u201329 (2016).","journal-title":"Diabetologia"},{"key":"2630_CR9","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/cphy.c120028","volume":"3","author":"JD Imig","year":"2013","unstructured":"Imig, J. D. & Ryan, M. J. Immune and inflammatory role in renal disease. Compr. Physiol. 3, 957\u2013976 (2013).","journal-title":"Compr. Physiol."},{"key":"2630_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/wrna.1","volume":"1","author":"DJ Stumpo","year":"2010","unstructured":"Stumpo, D. J., Lai, W. S. & Blackshear, P. J. Inflammation: cytokines and RNA-based regulation. Wiley Interdiscip. Rev. RNA 1, 60\u201380 (2010).","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"2630_CR11","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.tips.2016.07.002","volume":"37","author":"S Patial","year":"2016","unstructured":"Patial, S. & Blackshear, P. J. Tristetraprolin as a therapeutic target in inflammatory disease. Trends Pharm. Sci. 37, 811\u2013821 (2016).","journal-title":"Trends Pharm. Sci."},{"key":"2630_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08035-7","volume":"10","author":"YO Son","year":"2019","unstructured":"Son, Y. O., Kim, H. E., Choi, W. S., Chun, C. H. & Chun, J. S. RNA-binding protein ZFP36L1 regulates osteoarthritis by modulating members of the heat shock protein 70 family. Nat. Commun. 10, 77 (2019).","journal-title":"Nat. Commun."},{"key":"2630_CR13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.03390","volume":"4","author":"MA Hausburg","year":"2015","unstructured":"Hausburg, M. A. et al. Post-transcriptional regulation of satellite cell quiescence by TTP-mediated mRNA decay. Elife 4, e03390 (2015).","journal-title":"Elife"},{"key":"2630_CR14","doi-asserted-by":"publisher","first-page":"47767","DOI":"10.18632\/oncotarget.17770","volume":"8","author":"PM Krishnamurthy","year":"2017","unstructured":"Krishnamurthy, P. M. et al. Involvement of p38-betaTrCP-Tristetraprolin-TNFalpha axis in radiation pneumonitis. Oncotarget 8, 47767\u201347779 (2017).","journal-title":"Oncotarget"},{"key":"2630_CR15","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.preteyeres.2010.08.003","volume":"29","author":"TK Khera","year":"2010","unstructured":"Khera, T. K., Dick, A. D. & Nicholson, L. B. Mechanisms of TNFalpha regulation in uveitis: focus on RNA-binding proteins. Prog. Retin. Eye Res. 29, 610\u2013621 (2010).","journal-title":"Prog. Retin. Eye Res."},{"key":"2630_CR16","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1136\/annrheumdis-2016-209424","volume":"76","author":"EA Ross","year":"2017","unstructured":"Ross, E. A. et al. Treatment of inflammatory arthritis via targeting of tristetraprolin, a master regulator of pro-inflammatory gene expression. Ann. Rheum. Dis. 76, 612\u2013619 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"2630_CR17","doi-asserted-by":"publisher","first-page":"14451","DOI":"10.1007\/s13277-016-5397-z","volume":"37","author":"H Wang","year":"2016","unstructured":"Wang, H., Ding, N., Guo, J., Xia, J. & Ruan, Y. Dysregulation of TTP and HuR plays an important role in cancers. Tumour Biol. 37, 14451\u201314461 (2016).","journal-title":"Tumour Biol."},{"key":"2630_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06081-7","volume":"7","author":"K Khalaj","year":"2017","unstructured":"Khalaj, K. et al. A balancing act: RNA binding protein HuR\/TTP axis in endometriosis patients. Sci. Rep. 7, 5883 (2017).","journal-title":"Sci. Rep."},{"key":"2630_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fgene.2019.00031","volume":"10","author":"DH Ostareck","year":"2019","unstructured":"Ostareck, D. H. & Ostareck-Lederer, A. RNA-binding proteins in the control of LPS-induced macrophage response. Front Genet. 10, 31 (2019).","journal-title":"Front Genet."},{"key":"2630_CR20","first-page":"42","volume":"21","author":"T Beiter","year":"2015","unstructured":"Beiter, T. et al. Exercise, skeletal muscle and inflammation: ARE-binding proteins as key regulators in inflammatory and adaptive networks. Exerc. Immunol. Rev. 21, 42\u201357 (2015).","journal-title":"Exerc. Immunol. Rev."},{"key":"2630_CR21","unstructured":"Council, N. R. Guide for the Care and Use of Laboratory Animals. (The National Academies Press, 1996)."},{"key":"2630_CR22","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1681\/ASN.2015050565","volume":"27","author":"S Zhou","year":"2016","unstructured":"Zhou, S. et al. Genetic and pharmacologic targeting of glycogen synthase kinase 3beta reinforces the Nrf2 antioxidant defense against podocytopathy. J. Am. Soc. Nephrol. 27, 2289\u20132308 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2630_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/sj.ki.5002291","volume":"72","author":"SJ Shankland","year":"2007","unstructured":"Shankland, S. J., Pippin, J. W., Reiser, J. & Mundel, P. Podocytes in culture: past, present, and future. Kidney Int. 72, 26\u201336 (2007).","journal-title":"Kidney Int."},{"key":"2630_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/srep22579","volume":"6","author":"W Bao","year":"2016","unstructured":"Bao, W. et al. Toll-like receptor 9 can be activated by endogenous mitochondrial DNA to induce podocyte apoptosis. Sci. Rep. 6, 22579 (2016).","journal-title":"Sci. Rep."},{"key":"2630_CR25","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/pmic.200300771","volume":"4","author":"N Blom","year":"2004","unstructured":"Blom, N., Sicheritz-Ponten, T., Gupta, R., Gammeltoft, S. & Brunak, S. Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 4, 1633\u20131649 (2004).","journal-title":"Proteomics"},{"key":"2630_CR26","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1093\/carcin\/bgt207","volume":"34","author":"A Sharma","year":"2013","unstructured":"Sharma, A., Bhat, A. A., Krishnan, M., Singh, A. B. & Dhawan, P. Trichostatin-A modulates claudin-1 mRNA stability through the modulation of Hu antigen R and tristetraprolin in colon cancer cells. Carcinogenesis 34, 2610\u20132621 (2013).","journal-title":"Carcinogenesis"},{"key":"2630_CR27","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.4049\/jimmunol.1301188","volume":"191","author":"J Chen","year":"2013","unstructured":"Chen, J. et al. Posttranscriptional gene regulation of IL-17 by the RNA-binding protein HuR is required for initiation of experimental autoimmune encephalomyelitis. J. Immunol. 191, 5441\u20135450 (2013).","journal-title":"J. Immunol."},{"key":"2630_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.febslet.2011.11.021","volume":"586","author":"HH Lee","year":"2012","unstructured":"Lee, H. H. et al. Tristetraprolin down-regulates IL-17 through mRNA destabilization. FEBS Lett. 586, 41\u201346 (2012).","journal-title":"FEBS Lett."},{"key":"2630_CR29","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1042\/BST0320803","volume":"32","author":"S Patel","year":"2004","unstructured":"Patel, S., Doble, B. & Woodgett, J. R. Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword? Biochem. Soc. Trans. 32, 803\u2013808 (2004).","journal-title":"Biochem. Soc. Trans."},{"key":"2630_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/cns.12683","volume":"23","author":"S Huang","year":"2017","unstructured":"Huang, S. et al. GSK-3beta inhibitor TDZD-8 reduces neonatal hypoxic-ischemic brain injury in mice. CNS Neurosci. Ther. 23, 405\u2013415 (2017).","journal-title":"CNS Neurosci. Ther."},{"key":"2630_CR31","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1042\/BST20160166","volume":"44","author":"AR Clark","year":"2016","unstructured":"Clark, A. R. & Dean, J. L. The control of inflammation via the phosphorylation and dephosphorylation of tristetraprolin: a tale of two phosphatases. Biochem. Soc. Trans. 44, 1321\u20131337 (2016).","journal-title":"Biochem. Soc. Trans."},{"key":"2630_CR32","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/msb.2013.12","volume":"9","author":"RH Newman","year":"2013","unstructured":"Newman, R. H. et al. Construction of human activity-based phosphorylation networks. Mol. Syst. Biol. 9, 655 (2013).","journal-title":"Mol. Syst. Biol."},{"key":"2630_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1042\/BJ20051316","volume":"394","author":"H Cao","year":"2006","unstructured":"Cao, H. et al. Identification of the anti-inflammatory protein tristetraprolin as a hyperphosphorylated protein by mass spectrometry and site-directed mutagenesis. Biochem. J. 394, 285\u2013297 (2006).","journal-title":"Biochem. J."},{"key":"2630_CR34","doi-asserted-by":"publisher","unstructured":"Grammatikakis, I., Abdelmohsen, K. & Gorospe, M. Posttranslational control of HuR function. Wiley Interdiscip. Rev. RNA 8, https:\/\/doi.org\/10.1002\/wrna.1372 (2017).","DOI":"10.1002\/wrna.1372"},{"key":"2630_CR35","doi-asserted-by":"publisher","first-page":"380","DOI":"10.2174\/138920312801619439","volume":"13","author":"W Eberhardt","year":"2012","unstructured":"Eberhardt, W., Doller, A. & Pfeilschifter, J. Regulation of the mRNA-binding protein HuR by posttranslational modification: spotlight on phosphorylation. Curr. Protein Pept. Sci. 13, 380\u2013390 (2012).","journal-title":"Curr. Protein Pept. Sci."},{"key":"2630_CR36","doi-asserted-by":"publisher","first-page":"10015","DOI":"10.3390\/ijms140510015","volume":"14","author":"J Wang","year":"2013","unstructured":"Wang, J. et al. Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis. Int. J. Mol. Sci. 14, 10015\u201310041 (2013).","journal-title":"Int. J. Mol. Sci."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2630-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2630-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2630-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T09:59:25Z","timestamp":1670234365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2630-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["2630"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-2630-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,2]]},"assertion":[{"value":"6 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"413"}}